Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-17512 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- BRCA1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- It is not recommended to aliquot this antibody.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 16 µg/mL
- Storage
- -20°C
Submitted references BRCA1 Antibodies Matter.
Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells.
Yang J, Qi L, Chiang HC, Yuan B, Li R, Hu Y
International journal of biological sciences 2021;17(12):3239-3254
International journal of biological sciences 2021;17(12):3239-3254
Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells.
Syeda MM, Upadhyay K, Loke J, Pearlman A, Klugman S, Shao Y, Ostrer H
Genetics in medicine : official journal of the American College of Medical Genetics 2017 Sep;19(9):1071-1077
Genetics in medicine : official journal of the American College of Medical Genetics 2017 Sep;19(9):1071-1077
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of BRCA1 in untreated and UV-treated (50 mJ/cm2, 30 min) HeLa cells using BRCA1 polyclonal antibody (Product # PA5-17512).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Analysis of BRCA1 antibodies by immunoprecipitation in human cell lines. (A) BRCA1 IPs with 293T/3XFlag-hBRCA1 stably transfected cell lysate. (B) BRCA1 IPs with U2OS/3xFLAG-APEX2-fused BRCA1 cell lysate. (C) BRCA1 IPs with MDA-MB-468 cell lysate.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Analysis of BRCA1 antibodies by ChIP-qPCR in human cancer cells. (A) BRCA1 immunoblots with CTT20 (inducible Cas9 in HeLa), A9.2 and A10.2 (two BRCA1 inducible KO cell lines) cells with/without doxycycline treatment. (B-F) ChIP-qPCR profiles of CTT20 (inducible Cas9 in HeLa), A9.2 and A10.2 cells with/without doxycycline treatment using BRCA1(Ab1) antibody at the BRCA1 (B), ATRIP (C), EXO1 (D), MAD2L1 (E) and PPM1D (F) promoter regions. 6 mug of Ab (if concentration of Ab is provided) or 15 mul of serum (if concentration is not provided) is used. **p < 0.01, *p < 0.05, Student's t-test.